The European Pharmaceutical Industry in the 1990's
Author : Gabriele Kammradt
Publisher :
Page : 84 pages
File Size : 11,57 MB
Release : 1989
Category :
ISBN :
Author : Gabriele Kammradt
Publisher :
Page : 84 pages
File Size : 11,57 MB
Release : 1989
Category :
ISBN :
Author : Paul Drosten
Publisher :
Page : pages
File Size : 27,59 MB
Release : 1990
Category : Pharmaceutical industry
ISBN :
Author : Barrie G. James
Publisher :
Page : 116 pages
File Size : 11,37 MB
Release : 1990
Category : Business & Economics
ISBN :
Author : Arne Noack
Publisher : GRIN Verlag
Page : 54 pages
File Size : 25,44 MB
Release : 2007-11
Category : Business & Economics
ISBN : 3638726703
Seminar paper from the year 2003 in the subject Business economics - Operations Research, grade: A, Vrije University Brussel (Vesalius College), course: Economics, language: English, abstract: The health of their population has always been a great concern for governments of Post-War Europe. In order to achieve their goals they had to work closely together with the pharmaceutical Industry. With the phenomenon of the aging population the importance of development of new drugs is increasing. The increasingly old population of Europe creates a big market for pharmaceutical companies. The pharmaceutical Industry is a very complex sector with close links to other Industries. The chemical Industry for example is an important supplier for materials needed in the process of creating new drugs. Furthermore is the market for pharmaceuticals characterized by extremely little concentration and a huge variety of products. Globally in 1998, the 300 best-selling products held a share of less than 45% of the worlds market. The top two products held 1.3% of the market each.1 This fact creates a necessity for the companies to research new, so called "Blockbuster drugs" to succeed on this market with a high competition. The data on the various methods of drug discovery is enormous and sophisticated. In this paper the structure of the Research & Development sector of the European pharmaceutical industry will be examined, which is of increasing importance for the success of the individual companies. The specific data on the R & D section will be given a general character. Furthermore it will give a brief overview of the different regions in Europe and their individual differences. In the end, the difficulties and challenges of R & D in the pharmaceutical industry will be described and compared to other pharma markets abroad. [1 Data taken from "Combining discovery with development" by Dr. Peter Eddershaw; World pharmaceutical frontiers 2003/2004 ]
Author : Institute of Medicine
Publisher : National Academies Press
Page : 225 pages
File Size : 29,62 MB
Release : 1991-02-01
Category : Medical
ISBN : 030904491X
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Author : Folashade Bosede Awoniyi
Publisher :
Page : pages
File Size : 41,52 MB
Release : 1991
Category :
ISBN :
Author : Anita M. McGahan
Publisher :
Page : 0 pages
File Size : 17,7 MB
Release : 1995
Category :
ISBN :
Author :
Publisher :
Page : 522 pages
File Size : 43,10 MB
Release : 1994
Category : Pharmaceutical industry
ISBN :
Author : Meir Perez Pugatch
Publisher : Edward Elgar Publishing
Page : 298 pages
File Size : 11,91 MB
Release : 2004-01-01
Category : Law
ISBN : 9781845420741
'This book is a substantial contribution to the discussion on trade-related intellectual property rights. It provides a clear, step-by-step, in-depth analysis of the TRIPS agreement, particularly as it relates to the European pharmaceutical industry. Politics, law and economics are judiciously blended. Meir Pugatch's work should be read not just by academic experts and students in the field, but also by trade policy and IPR practitioners interested in an accessible, policy-relevant treatment of the issues at hand.' - Razeen Sally, London School of Economics and Political Science, UK This book investigates the realm of intellectual property rights (IPRs) within the context of international political economy. In particular, it examines the extent to which powerful interest groups, such as pharmaceutical multinational companies, influence the political dynamism underlying the field of IPRs. Meir Perez Pugatch argues that a pure economic approach does not provide a sufficient or satisfactory explanation for the creation of intellectual property rights, most notably patents. The author instead suggests that a dynamic approach, based on the international political economy of interest groups and systemic outcomes, provides a better starting point for explaining how the international intellectual property agenda is determined.
Author : Congressional Budget Office
Publisher : Lulu.com
Page : 65 pages
File Size : 40,53 MB
Release : 2013-06-09
Category : Science
ISBN : 1304121445
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...